Genedrive plc (LSE:GDR) has welcomed the publication of a new UK clinical guideline endorsing MT-RNR1 genotype testing before the use of aminoglycoside antibiotics in situations where results can be delivered quickly enough to influence treatment decisions. The Manchester-based diagnostics company believes the guidance strengthens the case for broader adoption of its rapid point-of-care genetic testing technology across the NHS and supports its strategy of expanding precision medicine in acute healthcare settings.
New Guidance Endorses Rapid Genetic Testing
The guideline, published in the British Journal of Clinical Pharmacology, recommends testing patients for MT-RNR1 genetic variants before administering aminoglycoside antibiotics whenever clinically relevant turnaround times can be achieved. The publication also recognises the value of point-of-care testing and specifically references the Genedrive MT-RNR1 ID Kit, which is currently the only point-of-care MT-RNR1 test routinely used in neonatal intensive care units across the UK.
Management described the new guidance as an important step towards increasing the adoption of pharmacogenetic testing within emergency and neonatal care.
NHS Expansion Opportunity Strengthens Growth Prospects
According to Genedrive, the clinical guideline complements the existing NICE Early Value Assessment, which concluded that the MT-RNR1 ID Kit has the potential to improve patient outcomes while reducing healthcare costs compared with standard treatment pathways.
The company expects additional evidence from the PALOH-UK programme to contribute to NICE’s planned review, which could further support wider NHS deployment of the test. If adopted more broadly, the technology could strengthen Genedrive’s commercial position in the growing pharmacogenomics market while creating new opportunities for revenue growth in the UK and overseas.
Financial Performance Continues to Present Challenges
Despite the positive clinical developments, Genedrive continues to face financial headwinds. The company remains loss-making, continues to consume cash and has seen its equity base decline, although debt levels remain relatively low.
Technical indicators offer a more balanced outlook, with the share price trading above its major moving averages and momentum signals remaining broadly neutral. However, valuation remains constrained by the absence of earnings and a lack of dividend support.
About Genedrive plc
Genedrive plc is a UK commercial-stage molecular diagnostics company specialising in rapid point-of-care pharmacogenetic testing. Its products are designed to help clinicians make safer prescribing decisions in emergency and acute care by identifying genetic variations that influence a patient’s response to specific medicines.
The company’s portfolio includes the Genedrive CYP2C19 ID Kit, which identifies stroke patients who may not respond effectively to Clopidogrel, and the MT-RNR1 ID Kit, which helps prevent aminoglycoside-related hearing loss in newborns. Through these technologies, Genedrive aims to expand the use of precision medicine across healthcare systems in the UK and international markets.
Leave a Reply